ibuprofen has been researched along with Alzheimer Disease in 66 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibuprofen protected the increase of myo-inositol at six months of age in the hippocampus, but had no effect at 17-23 months of age (a time when Aβ is extracellular)." | 5.40 | The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging. ( Aytan, N; Carreras, I; Choi, JK; Dedeoglu, A; Jenkins, BG; Jenkins-Sahlin, E, 2014) |
| "Ibuprofen is a member of the proprionic acid group of nonsteroidal anti-inflammatory drugs (NSAID), with the S-enantiomer being more active than the R-enantiomer." | 5.35 | Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease. ( Chen, WN; Ching, CB; Sui, J; Zhang, J, 2008) |
| "The brain in Alzheimer's disease (AD) shows a chronic inflammatory response characterized by activated glial cells and increased expression of cytokines and complement factors surrounding amyloid deposits." | 5.31 | Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. ( Ashe, KH; Beech, W; Chen, P; Chu, T; Cole, GM; Frautschy, SA; Lim, GP; Teter, B; Tran, T; Ubeda, O; Yang, F, 2000) |
| "There is epidemiological observation that long-term treatment of patients suffering from rheumatoid arthritis with ibuprofen results in reduced risk and delayed onset of Alzheimer's disease (AD)." | 4.82 | Ibuprofen and Alzheimer's disease. ( Dokmeci, D, 2004) |
| " Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset." | 2.43 | Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. ( Praticò, D; Townsend, KP, 2005) |
| "Current drugs available in clinic for Alzheimer's disease (AD) treatment can only alleviate disease symptoms without clearly curing or delaying the process of AD." | 1.62 | ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker. ( Fang, L; Gou, S; Liu, Z; Xia, S; Zhang, B, 2021) |
| "Alzheimer's disease is a progressive brain disorder with characteristic symptoms and several pathological hallmarks." | 1.62 | 2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease. ( Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M, 2021) |
| "Despite Alzheimer's disease (AD) incidence being projected to increase worldwide, the drugs currently on the market can only mitigate symptoms." | 1.62 | From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease. ( Albertini, C; Bartolini, M; Bolognesi, ML; Grifoni, D; Monti, B; Naldi, M; Petralla, S; Strocchi, S, 2021) |
| "Cromolyn sodium is an asthma therapeutic agent previously shown to reduce Aβ levels in transgenic AD mouse brains after one-week of treatment." | 1.48 | Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. ( Elmaleh, DR; Forte, AM; Griciuc, A; Hudry, E; Quinti, L; Ran, C; Shen, X; Tanzi, RE; Wan, Y; Ward, J; Zhang, C, 2018) |
| "Identifying preventive targets for Alzheimer's disease is a central challenge of modern medicine." | 1.43 | Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. ( Andreasson, KI; Boutaud, O; Brown, H; Chuluun, B; Colas, D; Heller, HC; Khroyan, TV; Ko, N; Liang, X; Manning-Boğ, AB; Mhatre, SD; Milne, GL; Minhas, P; Panchal, M; Priyam, PG; Rassoulpour, A; van der Hart, M; Wang, Q; Woodling, NS; Zagol-Ikapitte, I, 2016) |
| "Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), treatment with which has been shown to delay the onset, slows the cognitive decline, and decreases the incidence of Alzheimer׳s disease (AD) in epidemiological and clinical studies." | 1.42 | The influence of chronic ibuprofen treatment on proteins expressed in the mouse hippocampus. ( Kadoyama, K; Matsuura, K; Matsuyama, S; Otani, M; Takano, M, 2015) |
| "Ibuprofen is a widely used nonsteroidal anti-inflammatory drug that reportedly reduces the risk of Alzheimer's disease (AD) development." | 1.40 | Ibuprofen partially attenuates neurodegenerative symptoms in presenilin conditional double-knockout mice. ( Dong, Z; Huang, G; Mei, B; Meng, B; Yan, L; Zhang, L, 2014) |
| "Ibuprofen protected the increase of myo-inositol at six months of age in the hippocampus, but had no effect at 17-23 months of age (a time when Aβ is extracellular)." | 1.40 | The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging. ( Aytan, N; Carreras, I; Choi, JK; Dedeoglu, A; Jenkins, BG; Jenkins-Sahlin, E, 2014) |
| "Ibuprofen treatment reduced levels of lipid peroxidation, tyrosine nitration, and protein oxidation, demonstrating a dramatic effect on oxidative damage in vivo." | 1.38 | Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. ( Cramer, PE; Herrup, K; Jiang, Q; Lamb, BT; Landreth, GE; Reed-Geaghan, E; Szabo, A; Varvel, NH; Wilkinson, BL, 2012) |
| "Hypertension and sporadic Alzheimer's disease (AD) have been associated but clear pathophysiological links have not yet been demonstrated." | 1.38 | Role of neuroinflammation in hypertension-induced brain amyloid pathology. ( Ajmone-Cat, MA; Alleva, E; Branchi, I; Carnevale, D; Carnevale, L; Carullo, P; Cifelli, G; Cocozza, G; D'Andrea, I; Frati, A; Lembo, G; Madonna, M; Mascio, G; Minghetti, L, 2012) |
| "Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that has been reported to reduce the risk of developing Alzheimer's disease (AD)." | 1.38 | No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. ( Bayer, TA; Bulic, B; Demuth, HU; Hahn, S; Hillmann, A; Hoffmann, T; Schilling, S; Schneider-Axmann, T; Weggen, S; Wirths, O, 2012) |
| "Alzheimer's disease is a neurodegenerative pathology due to the presence of β-amyloid plaques at brain level and hippocampus level and associated with the loss of memory speech and learning." | 1.37 | NOS-mediated morphological and molecular modifications in rats infused with Aβ (1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1. ( Cataldi, A; Cerasa, LS; Di Stefano, A; Nasuti, C; Patruno, A; Pesce, M; Rapino, M; Sozio, P; Zara, S, 2011) |
| "Ibuprofen-treated APP23 mice performed significantly better than their sham-treated counterparts and almost attained the same level of performance as control animals on a complex visual-spatial learning task." | 1.36 | Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. ( Coen, K; De Deyn, PP; Van Dam, D, 2010) |
| "Ibuprofen treatment significantly reduced microglia area in cortex and hippocampus but not beta-amyloid burden." | 1.35 | CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. ( Cenacchi, V; Facchinetti, F; Hutter-Paier, B; Imbimbo, BP; Lanzillotta, A; Pizzi, M; Villetti, G; Volta, R; Windisch, M, 2009) |
| "Ibuprofen was linked directly to the C-2, C-3, C-4, and C-6 positions of glucose via ester bonds." | 1.35 | Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. ( Chen, Q; Fu, H; Gong, T; Liu, J; Wang, X; Zhang, Z, 2009) |
| " Retrospective human epidemiological studies have identified long-term use of NSAIDs as protective against AD." | 1.35 | NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. ( Bhaskar, K; Herrup, K; Kounnas, MZ; Lamb, BT; Varvel, NH; Wagner, SL; Yang, Y, 2009) |
| "Ibuprofen is a member of the proprionic acid group of nonsteroidal anti-inflammatory drugs (NSAID), with the S-enantiomer being more active than the R-enantiomer." | 1.35 | Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease. ( Chen, WN; Ching, CB; Sui, J; Zhang, J, 2008) |
| "Ibuprofen-treated transgenic mice showed a significant decrease in intraneuronal oligomeric Abeta and hyperphosphorylated tau (AT8) immunoreactivity in the hippocampus." | 1.35 | Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. ( Carreras, I; Dedeoglu, A; Hossain, L; Jenkins, BG; Klein, WL; Kowall, NW; LaFerla, FM; McKee, AC; Oddo, S; Ryu, H, 2008) |
| "Curcumin was a better Abeta40 aggregation inhibitor than ibuprofen and naproxen, and prevented Abeta42 oligomer formation and toxicity between 0." | 1.33 | Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. ( Ambegaokar, SS; Begum, AN; Chen, PP; Cole, GM; Frautschy, SA; Glabe, CG; Kayed, R; Lim, GP; Simmons, MR; Ubeda, OJ; Yang, F, 2005) |
| "Neuritic plaques in the brain of Alzheimer's disease patients are characterized by beta-amyloid deposits associated with a glia-mediated inflammatory response." | 1.33 | Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. ( Dewachter, I; Dumitrescu-Ozimek, L; Hanke, A; Heneka, MT; Klockgether, T; Kuiperi, C; Landreth, GE; O'Banion, K; Sastre, M; Van Leuven, F, 2005) |
| "Epidemiological studies have suggested that the chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the relative risk of Alzheimer's disease (AD)." | 1.32 | In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. ( Agdeppa, ED; Barrio, JR; Cole, GM; Huang, SC; Kepe, V; Liu, J; Petri, A; Satyamurthy, N; Small, GW, 2003) |
| "Ibuprofen treatment resulted in 60% reduction of amyloid plaque load in the cortex of these animals." | 1.32 | Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. ( Babu-Khan, S; Biere, AL; Citron, M; Landreth, G; Liu, H; Vassar, R; Yan, Q; Zhang, J, 2003) |
| "Ibuprofen treatment reduced the numbers of reactive astrocytes following aggregated Abeta injection, and withdrawal of ibuprofen resulted in an increase of reactive astrocytes." | 1.31 | Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. ( Cleary, J; Gardiner, T; Kim, EM; O'Hare, E; Richardson, RL; Shephard, RA, 2002) |
| "The brain in Alzheimer's disease (AD) shows a chronic inflammatory response characterized by activated glial cells and increased expression of cytokines and complement factors surrounding amyloid deposits." | 1.31 | Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. ( Ashe, KH; Beech, W; Chen, P; Chu, T; Cole, GM; Frautschy, SA; Lim, GP; Teter, B; Tran, T; Ubeda, O; Yang, F, 2000) |
| "Ibuprofen treatment decreased the secretion of total Abeta in the conditioned media of cytokine stimulated cells by 50% and prevented the accumulation of Abeta-42 and Abeta-40 in detergent soluble cell extracts." | 1.31 | Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. ( Apochal, A; Blasko, I; Boeck, G; Grubeck-Loebenstein, B; Hartmann, T; Ransmayr, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.52) | 18.2507 |
| 2000's | 34 (51.52) | 29.6817 |
| 2010's | 25 (37.88) | 24.3611 |
| 2020's | 6 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Stock, N | 1 |
| Munoz, B | 1 |
| Wrigley, JD | 1 |
| Shearman, MS | 1 |
| Beher, D | 1 |
| Peachey, J | 1 |
| Williamson, TL | 1 |
| Bain, G | 1 |
| Chen, W | 1 |
| Jiang, X | 1 |
| St-Jacques, R | 1 |
| Prasit, P | 1 |
| Cornec, AS | 1 |
| Monti, L | 1 |
| Kovalevich, J | 1 |
| Makani, V | 1 |
| James, MJ | 1 |
| Vijayendran, KG | 1 |
| Oukoloff, K | 1 |
| Yao, Y | 1 |
| Lee, VM | 1 |
| Trojanowski, JQ | 1 |
| Smith, AB | 1 |
| Brunden, KR | 1 |
| Ballatore, C | 1 |
| Dias Viegas, FP | 1 |
| de Freitas Silva, M | 1 |
| Divino da Rocha, M | 1 |
| Castelli, MR | 1 |
| Riquiel, MM | 1 |
| Machado, RP | 1 |
| Vaz, SM | 1 |
| Simões de Lima, LM | 1 |
| Mancini, KC | 1 |
| Marques de Oliveira, PC | 1 |
| Morais, ÉP | 1 |
| Gontijo, VS | 1 |
| da Silva, FMR | 1 |
| D'Alincourt da Fonseca Peçanha, D | 1 |
| Castro, NG | 1 |
| Neves, GA | 1 |
| Giusti-Paiva, A | 1 |
| Vilela, FC | 1 |
| Orlandi, L | 1 |
| Camps, I | 1 |
| Veloso, MP | 1 |
| Leomil Coelho, LF | 1 |
| Ionta, M | 1 |
| Ferreira-Silva, GÁ | 1 |
| Pereira, RM | 1 |
| Dardenne, LE | 1 |
| Guedes, IA | 1 |
| de Oliveira Carneiro Junior, W | 1 |
| Quaglio Bellozi, PM | 1 |
| Pinheiro de Oliveira, AC | 1 |
| Ferreira, FF | 1 |
| Pruccoli, L | 1 |
| Tarozzi, A | 1 |
| Viegas, C | 1 |
| Liu, Z | 1 |
| Zhang, B | 2 |
| Xia, S | 1 |
| Fang, L | 1 |
| Gou, S | 1 |
| Mezeiova, E | 1 |
| Janockova, J | 1 |
| Andrys, R | 1 |
| Soukup, O | 1 |
| Kobrlova, T | 1 |
| Muckova, L | 1 |
| Pejchal, J | 1 |
| Simunkova, M | 1 |
| Handl, J | 1 |
| Micankova, P | 1 |
| Capek, J | 1 |
| Rousar, T | 1 |
| Hrabinova, M | 1 |
| Nepovimova, E | 1 |
| Marco-Contelles, JL | 1 |
| Valko, M | 1 |
| Korabecny, J | 1 |
| Hu, H | 1 |
| Wang, J | 1 |
| Ren, J | 1 |
| Li, X | 1 |
| Lv, Z | 1 |
| Dai, F | 1 |
| Kaur, S | 1 |
| Minhas, R | 1 |
| Mishra, S | 1 |
| Kaur, B | 1 |
| Bansal, Y | 1 |
| Bansal, G | 1 |
| McLarnon, JG | 1 |
| Albertini, C | 1 |
| Naldi, M | 1 |
| Petralla, S | 1 |
| Strocchi, S | 1 |
| Grifoni, D | 1 |
| Monti, B | 1 |
| Bartolini, M | 1 |
| Bolognesi, ML | 1 |
| Wen, MM | 1 |
| Ismail, NIK | 1 |
| Nasra, MMA | 1 |
| El-Kamel, AH | 1 |
| Ettcheto, M | 2 |
| Sánchez-López, E | 2 |
| Pons, L | 1 |
| Busquets, O | 1 |
| Olloquequi, J | 1 |
| Beas-Zarate, C | 1 |
| Pallas, M | 1 |
| García, ML | 2 |
| Auladell, C | 1 |
| Folch, J | 2 |
| Camins, A | 2 |
| Zhang, C | 2 |
| Griciuc, A | 1 |
| Hudry, E | 1 |
| Wan, Y | 1 |
| Quinti, L | 1 |
| Ward, J | 1 |
| Forte, AM | 1 |
| Shen, X | 1 |
| Ran, C | 1 |
| Elmaleh, DR | 1 |
| Tanzi, RE | 1 |
| Qin, H | 1 |
| Zheng, R | 1 |
| Wang, Y | 1 |
| Yan, T | 1 |
| Huan, F | 1 |
| Han, Y | 1 |
| Zhu, W | 1 |
| Zhang, L | 2 |
| Zara, S | 5 |
| De Colli, M | 1 |
| Rapino, M | 3 |
| Pacella, S | 1 |
| Nasuti, C | 5 |
| Sozio, P | 5 |
| Di Stefano, A | 5 |
| Cataldi, A | 5 |
| Zhang, X | 1 |
| Li, H | 1 |
| Mao, Y | 1 |
| Li, Z | 1 |
| Wang, R | 2 |
| Guo, T | 1 |
| Jin, L | 1 |
| Song, R | 1 |
| Xu, W | 1 |
| Zhou, N | 1 |
| Zhang, Y | 1 |
| Hu, R | 1 |
| Wang, X | 2 |
| Huang, H | 1 |
| Lei, Z | 1 |
| Niu, G | 1 |
| Irwin, DM | 1 |
| Tan, H | 1 |
| Dong, Z | 1 |
| Yan, L | 1 |
| Huang, G | 1 |
| Mei, B | 1 |
| Meng, B | 1 |
| Choi, JK | 2 |
| Carreras, I | 3 |
| Aytan, N | 1 |
| Jenkins-Sahlin, E | 1 |
| Dedeoglu, A | 3 |
| Jenkins, BG | 3 |
| Matsuura, K | 1 |
| Otani, M | 1 |
| Takano, M | 1 |
| Kadoyama, K | 1 |
| Matsuyama, S | 1 |
| DiBattista, AM | 1 |
| Dumanis, SB | 1 |
| Newman, J | 1 |
| Rebeck, GW | 1 |
| Woodling, NS | 1 |
| Colas, D | 1 |
| Wang, Q | 1 |
| Minhas, P | 1 |
| Panchal, M | 1 |
| Liang, X | 1 |
| Mhatre, SD | 1 |
| Brown, H | 1 |
| Ko, N | 1 |
| Zagol-Ikapitte, I | 1 |
| van der Hart, M | 1 |
| Khroyan, TV | 1 |
| Chuluun, B | 1 |
| Priyam, PG | 1 |
| Milne, GL | 1 |
| Rassoulpour, A | 1 |
| Boutaud, O | 1 |
| Manning-Boğ, AB | 1 |
| Heller, HC | 1 |
| Andreasson, KI | 1 |
| Malkki, H | 1 |
| Egea, MA | 1 |
| Espina, M | 1 |
| Calpena, AC | 1 |
| Van Dam, D | 1 |
| Coen, K | 1 |
| De Deyn, PP | 1 |
| Imbimbo, BP | 1 |
| Hutter-Paier, B | 1 |
| Villetti, G | 1 |
| Facchinetti, F | 1 |
| Cenacchi, V | 1 |
| Volta, R | 1 |
| Lanzillotta, A | 1 |
| Pizzi, M | 1 |
| Windisch, M | 1 |
| Babiloni, C | 1 |
| Frisoni, GB | 1 |
| Del Percio, C | 1 |
| Zanetti, O | 2 |
| Bonomini, C | 2 |
| Cassetta, E | 1 |
| Pasqualetti, P | 2 |
| Miniussi, C | 1 |
| De Rosas, M | 1 |
| Valenzano, A | 1 |
| Cibelli, G | 1 |
| Eusebi, F | 1 |
| Rossini, PM | 2 |
| Dal Forno, G | 1 |
| Paulon, L | 1 |
| Sinforiani, E | 1 |
| Marra, C | 1 |
| Chen, Q | 1 |
| Gong, T | 1 |
| Liu, J | 2 |
| Fu, H | 1 |
| Zhang, Z | 1 |
| Kaymakcalan, S | 1 |
| Cormier, K | 1 |
| Kowall, NW | 3 |
| Varvel, NH | 2 |
| Bhaskar, K | 1 |
| Kounnas, MZ | 1 |
| Wagner, SL | 1 |
| Yang, Y | 1 |
| Lamb, BT | 2 |
| Herrup, K | 2 |
| D'Aurizio, E | 2 |
| Iannitelli, A | 2 |
| Cantalamessa, F | 1 |
| Wilkinson, BL | 1 |
| Cramer, PE | 1 |
| Reed-Geaghan, E | 1 |
| Jiang, Q | 1 |
| Szabo, A | 1 |
| Landreth, GE | 2 |
| Carnevale, D | 1 |
| Mascio, G | 1 |
| Ajmone-Cat, MA | 1 |
| D'Andrea, I | 1 |
| Cifelli, G | 1 |
| Madonna, M | 1 |
| Cocozza, G | 1 |
| Frati, A | 1 |
| Carullo, P | 1 |
| Carnevale, L | 1 |
| Alleva, E | 1 |
| Branchi, I | 1 |
| Lembo, G | 1 |
| Minghetti, L | 1 |
| Patruno, A | 1 |
| Pesce, M | 1 |
| Cerasa, LS | 1 |
| Pinnen, F | 1 |
| Cacciatore, I | 1 |
| Cornacchia, C | 1 |
| Mollica, A | 1 |
| Hillmann, A | 1 |
| Hahn, S | 1 |
| Schilling, S | 1 |
| Hoffmann, T | 1 |
| Demuth, HU | 1 |
| Bulic, B | 1 |
| Schneider-Axmann, T | 1 |
| Bayer, TA | 1 |
| Weggen, S | 2 |
| Wirths, O | 1 |
| Knight, EM | 1 |
| Brown, TM | 1 |
| Gümüsgöz, S | 1 |
| Smith, JC | 1 |
| Waters, EJ | 1 |
| Allan, SM | 1 |
| Lawrence, CB | 1 |
| Richardson, RL | 1 |
| Kim, EM | 1 |
| Shephard, RA | 1 |
| Gardiner, T | 1 |
| Cleary, J | 1 |
| O'Hare, E | 1 |
| Pasinetti, GM | 2 |
| Agdeppa, ED | 1 |
| Kepe, V | 1 |
| Petri, A | 1 |
| Satyamurthy, N | 1 |
| Huang, SC | 1 |
| Small, GW | 1 |
| Cole, GM | 4 |
| Barrio, JR | 1 |
| Tabet, N | 1 |
| Feldmand, H | 1 |
| Yan, Q | 1 |
| Zhang, J | 2 |
| Liu, H | 1 |
| Babu-Khan, S | 1 |
| Vassar, R | 1 |
| Biere, AL | 1 |
| Citron, M | 1 |
| Landreth, G | 2 |
| Qin, W | 1 |
| Ho, L | 1 |
| Pompl, PN | 1 |
| Peng, Y | 1 |
| Zhao, Z | 1 |
| Xiang, Z | 1 |
| Robakis, NK | 1 |
| Shioi, J | 1 |
| Suh, J | 1 |
| Dokmeci, D | 1 |
| Yang, F | 3 |
| Lim, GP | 3 |
| Begum, AN | 1 |
| Ubeda, OJ | 1 |
| Simmons, MR | 1 |
| Ambegaokar, SS | 1 |
| Chen, PP | 1 |
| Kayed, R | 1 |
| Glabe, CG | 1 |
| Frautschy, SA | 3 |
| Farías, GG | 1 |
| Godoy, JA | 1 |
| Vázquez, MC | 1 |
| Adani, R | 1 |
| Meshulam, H | 1 |
| Avila, J | 1 |
| Amitai, G | 1 |
| Inestrosa, NC | 1 |
| Morihara, T | 1 |
| Teter, B | 2 |
| Boudinot, S | 1 |
| Boudinot, FD | 1 |
| Aizen, E | 1 |
| Kagan, G | 1 |
| Assy, B | 1 |
| Iobel, R | 1 |
| Bershadsky, Y | 1 |
| Gilhar, A | 1 |
| Heneka, MT | 2 |
| Sastre, M | 2 |
| Dumitrescu-Ozimek, L | 2 |
| Hanke, A | 1 |
| Dewachter, I | 2 |
| Kuiperi, C | 1 |
| O'Banion, K | 1 |
| Klockgether, T | 2 |
| Van Leuven, F | 2 |
| LeVine, H | 1 |
| Townsend, KP | 1 |
| Praticò, D | 1 |
| Balashov, AM | 1 |
| Rossner, S | 1 |
| Bogdanovic, N | 1 |
| Rosen, E | 1 |
| Borghgraef, P | 1 |
| Evert, BO | 1 |
| Thal, DR | 1 |
| Walter, J | 1 |
| Sui, J | 1 |
| Ching, CB | 1 |
| Chen, WN | 1 |
| McKee, AC | 1 |
| Hossain, L | 1 |
| Ryu, H | 1 |
| Klein, WL | 1 |
| Oddo, S | 1 |
| LaFerla, FM | 1 |
| Vlad, SC | 1 |
| Miller, DR | 1 |
| Felson, DT | 1 |
| Hooten, WM | 1 |
| Pearlson, G | 1 |
| Chu, T | 1 |
| Chen, P | 1 |
| Beech, W | 1 |
| Tran, T | 1 |
| Ubeda, O | 1 |
| Ashe, KH | 1 |
| Wyss-Coray, T | 1 |
| Mucke, L | 1 |
| Ogawa, O | 1 |
| Umegaki, H | 1 |
| Sumi, D | 1 |
| Hayashi, T | 1 |
| Nakamura, A | 1 |
| Thakur, NK | 1 |
| Yoshimura, J | 1 |
| Endo, H | 1 |
| Iguchi, A | 1 |
| Eriksen, JL | 1 |
| Das, P | 1 |
| Sagi, SA | 1 |
| Pietrzik, CU | 1 |
| Findlay, KA | 1 |
| Smith, TE | 1 |
| Murphy, MP | 1 |
| Bulter, T | 1 |
| Kang, DE | 1 |
| Marquez-Sterling, N | 1 |
| Golde, TE | 1 |
| Koo, EH | 1 |
| Blasko, I | 1 |
| Apochal, A | 1 |
| Boeck, G | 1 |
| Hartmann, T | 1 |
| Grubeck-Loebenstein, B | 1 |
| Ransmayr, G | 1 |
| Jantzen, PT | 1 |
| Connor, KE | 1 |
| DiCarlo, G | 1 |
| Wenk, GL | 1 |
| Wallace, JL | 1 |
| Rojiani, AM | 1 |
| Coppola, D | 1 |
| Morgan, D | 1 |
| Gordon, MN | 1 |
| Press, D | 1 |
| Holzgrabe, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252] | Phase 1 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Curcumin and Yoga Exercise Effects in Veterans at Risk for Alzheimer's Disease[NCT01811381] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-20 | Active, not recruiting | ||
| A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Two Doses of Curcumin C3 Complex Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease[NCT00099710] | Phase 2 | 33 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| Open Label,Crossover,Pilot Study to Assess the Efficacy & Safety of Perispinal Admin.of Etanercept(Enbrel®) in Comb.w/Nutritional Supplements vs. Nutritional Supplements Alone in Subj. w/Mild to Mod. Alzheimer's Disease Receiving Std. Care.[NCT01716637] | Phase 1 | 12 participants (Anticipated) | Interventional | 2010-02-28 | Completed | ||
| Pioglitazone in Alzheimer Disease Progression[NCT00982202] | Phase 2 | 25 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Biomarkers of Nonsteroidal Anti-Inflammatories[NCT00239746] | Phase 1 | 40 participants (Anticipated) | Interventional | 2005-10-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ibuprofen and Alzheimer Disease
| Article | Year |
|---|---|
Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Dapsone; Drug Therapy, Combination; Humans; Ibuprofen; Inflammation; Min | 2019 |
Ibuprofen for Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen | 2003 |
Ibuprofen and Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Ibuprofen | 2004 |
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Animals, Genetically Modified; Anti-Inflammator | 2005 |
[Non-steroid anti-inflammatory drugs in the treatment of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Indome | 2005 |
3 trials available for ibuprofen and Alzheimer Disease
| Article | Year |
|---|---|
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Brain Mappin | 2009 |
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein | 2009 |
Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cerebral | 2005 |
58 other studies available for ibuprofen and Alzheimer Disease
| Article | Year |
|---|---|
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2006 |
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.
Topics: Alzheimer Disease; Animals; Arachidonate 5-Lipoxygenase; Chemistry Techniques, Synthetic; Cyclooxyge | 2017 |
Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.
Topics: Acetylcholinesterase; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inh | 2018 |
ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Boronic Acids; Cells, Cultured; Cholinesterase Inh | 2021 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Hydrophilic polymer driven crystallization self-assembly: an inflammatory multi-drug combination nanosystem against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celeco | 2021 |
Design, Synthesis and Evaluation of Benzimidazole Hybrids to Inhibit Acetylcholinesterase and COX for Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzimidazoles; Cholinesterase Inhibitors; Ibuprof | 2022 |
From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Cell Survival; Cromolyn Sodium; | 2021 |
Repurposing ibuprofen-loaded microemulsion for the management of Alzheimer's disease: evidence of potential intranasal brain targeting.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bra | 2021 |
Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; As | 2017 |
Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Asthmatic Ag | 2018 |
A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; ATP Binding Cassette Transporte | 2018 |
Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Cyclic AMP Response Element-Bin | 2013 |
An over expression APP model for anti-Alzheimer disease drug screening created by zinc finger nuclease technology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosi | 2013 |
Ibuprofen partially attenuates neurodegenerative symptoms in presenilin conditional double-knockout mice.
Topics: Age Factors; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Anti | 2014 |
The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging.
Topics: Aging; Alzheimer Disease; Amygdala; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Chemistr | 2014 |
The influence of chronic ibuprofen treatment on proteins expressed in the mouse hippocampus.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Hippocampus; Ibuprofen; Mice; M | 2015 |
Identification and modification of amyloid-independent phenotypes of APOE4 mice.
Topics: Age Factors; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipopr | 2016 |
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Cyclooxygenase Inhibitors; Disease Models, Animal; Dow | 2016 |
Alzheimer disease: NSAIDs protect neurons and preserve memory in a mouse model of AD.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Ibuprof | 2016 |
New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cell Line; Coculture Tec | 2017 |
Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model.
Topics: Aging; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cognition Disorders; Dis | 2010 |
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2009 |
Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Blood-Brain B | 2009 |
Anti-inflammatory treatment in AD mice protects against neuronal pathology.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroi | 2010 |
NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory | 2009 |
Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxid | 2010 |
Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, C | 2012 |
Role of neuroinflammation in hypertension-induced brain amyloid pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebrovascular Circulation; Disease Model | 2012 |
NOS-mediated morphological and molecular modifications in rats infused with Aβ (1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxid | 2011 |
Ibuprofen and glutathione conjugate as a potential therapeutic agent for treating Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxid | 2011 |
Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cyclooxygenase Inhibitors; Disea | 2011 |
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti | 2012 |
Age-related changes in core body temperature and activity in triple-transgenic Alzheimer's disease (3xTgAD) mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Ste | 2013 |
Your best bets for preventing Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Diet; Exercise | 2002 |
Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocyt | 2002 |
From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Brain; Clinical T | 2002 |
In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Autoradiogr | 2003 |
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory | 2003 |
Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2003 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory | 2005 |
Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models.
Topics: Acute-Phase Proteins; alpha 1-Antichymotrypsin; Alzheimer Disease; Amyloid Precursor Protein Secreta | 2005 |
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Amyloidosis; Animals | 2005 |
Multiple ligand binding sites on A beta(1-40) fibrils.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Binding Sites; Congo Red; Fluorescent Dyes | 2005 |
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secreta | 2006 |
Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cell Survival; Cells, Cultur | 2008 |
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice.
Topics: Adenosine Triphosphatases; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; | 2008 |
Protective effects of NSAIDs on the development of Alzheimer disease.
Topics: Age Factors; Aged; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal | 2008 |
Delirium caused by tacrine and ibuprofen interaction.
Topics: Aged; Alzheimer Disease; Delirium; Dose-Response Relationship, Drug; Drug Interactions; Female; Huma | 1996 |
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloidosis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Disease Mod | 2000 |
Ibuprofen, inflammation and Alzheimer disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Ibuprof | 2000 |
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antineoplastic Agents; Cell Line; Cyclooxygenase | 2000 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2002 |
Nonsteroidal drugs and Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen | 2002 |
[Ibuprofen for Alzheimer's?].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen | 2002 |